NouvSight001
Retinal Degenerative Diseases
PreclinicalFDA Orphan Drug Designation granted; IND planned for Q2 2026
Key Facts
Indication
Retinal Degenerative Diseases
Phase
Preclinical
Status
FDA Orphan Drug Designation granted; IND planned for Q2 2026
Company
About iRegene Therapeutics
A biotech company developing iPSC-based cell therapies for neurological and retinal diseases using an AI-integrated discovery platform.
View full company profile